Jakavi 10mg tablets |Ruxolitinib | MHP
JAKAVI 10MG
DESCRIPTION
Jakavi 10mg belongs to the classification of medications called anti-cancer drugs.Jakavi 10mg tablet is a Janus kinase inhibitor with discrimination for subtypes JAK1 and JAK2 of this enzyme. Jakavi 10mg prohibits dysregulated JAK signaling along with myelofibrosis. This regimen is not prescribed for use in patients below 18 years of age.
Jakavi 10mg tablet is prescription drug provided under supervision of medical oncologist.
 |
| jakavi 10mg |
MECHANISM OF ACTION
Ruxolitinib is also known as targeted treatment which targets and joints to the tyrosine kinase receptors and prohibits Janus Associated Kinases (JAK1 and JAK2) which Intercede the signaling of several cytokines and growth factors which are important for hematopoiesis and immune function. By irrevocable to these receptors, Ruxolitinib stops important pathways which develop cell division. Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) known to be analogue with dysregulated JAK1 and JAK2 signaling. Patients with MF who either carry the JAK2 V617 mutation or does not have the JAK2 V617F mutation may both respond to Ruxolitinib.PRODUCT DETAILS:
Brand :Jakavi
Ingredients : Ruxolitinib
Strength : 10mg
Manufactured : Novartis Ltd
Package : 56 tablets
Rapid absorption and not affected by food maximum plasma level is 1.5 hours.
Distribution:
Volume of distribution is 76.6 L plasma protein binding is 97%
Metabolism:
metabolized by CYP3A4
Elimination:
Excreted via urine 74% and unchanged drug is <1% and through urine 22%, <1 % as unchanged drug
If Platelet count >200 x10^9/L the prescribed dose is 20 mg PO BID
If Platelet count 100-200 x10^9/L the prescribed dose is 15 mg PO BID
If Platelet count 50 to <100 x10^9/L the prescribed dose is 5 mg PO BID
Titrate dose based on response; not to exceed 25 mg PO BID
Undergo CBC and platelet count prior starting and q2-4wk until doses are stabilized, and then as clinically used.
Non-melanoma skin cancers including basal cell, squamous cell, and Merkel cell carcinoma have resulted in patients administrated with Jakavi 10mg tablet. Do the periodic skin examinations.
Therapy with Jakavi 10mg tablet can resulted in thrombocytopenia, Anemia and neutropenia. Regulate thrombocytopenia by decreasing the dose or temporarily prohibit Jakavi 10mg. Platelet transfusions may be needed.
Risk of infection occurs by delay initiate treatment with Jakavi 10mg tablet until active serious infection have resolved.
Tuberculosis infection has been resulted in patients administrating Jakavi 10mg. monitor patients getting Jakavi 10mg tablet for signs and symptoms of active tuberculosis and manage promptly.
• Dyspnea
• Nasopharyngitis
• Headache
• Constipation
• Decreased RBC
• Reduce in platelet counts
• Nausea & Vomiting
• Sleeplessness
• Liver enzymes increased
• Diarrhea
• bleeding
• Swelling
• Neutropenia
• Dizziness
Ingredients : Ruxolitinib
Strength : 10mg
Manufactured : Novartis Ltd
Package : 56 tablets
ADME
Absorption:Rapid absorption and not affected by food maximum plasma level is 1.5 hours.
Distribution:
Volume of distribution is 76.6 L plasma protein binding is 97%
Metabolism:
metabolized by CYP3A4
Elimination:
Excreted via urine 74% and unchanged drug is <1% and through urine 22%, <1 % as unchanged drug
DOSAGE MANAGEMENT
Myelofibrosis :
Starting recommended doses for myelofibrosisIf Platelet count >200 x10^9/L the prescribed dose is 20 mg PO BID
If Platelet count 100-200 x10^9/L the prescribed dose is 15 mg PO BID
If Platelet count 50 to <100 x10^9/L the prescribed dose is 5 mg PO BID
Titrate dose based on response; not to exceed 25 mg PO BID
Polycythemia Vera :
The prescribed dose is 10mg PO BIDUndergo CBC and platelet count prior starting and q2-4wk until doses are stabilized, and then as clinically used.
PRECAUTIONS:
Progressive multifocal leukoencephalopathy (PML) has occurred with Jakavi 10mg treatment. If PML is suspected, discontinue Jakavi 10mg and evaluate.Non-melanoma skin cancers including basal cell, squamous cell, and Merkel cell carcinoma have resulted in patients administrated with Jakavi 10mg tablet. Do the periodic skin examinations.
Therapy with Jakavi 10mg tablet can resulted in thrombocytopenia, Anemia and neutropenia. Regulate thrombocytopenia by decreasing the dose or temporarily prohibit Jakavi 10mg. Platelet transfusions may be needed.
Risk of infection occurs by delay initiate treatment with Jakavi 10mg tablet until active serious infection have resolved.
Tuberculosis infection has been resulted in patients administrating Jakavi 10mg. monitor patients getting Jakavi 10mg tablet for signs and symptoms of active tuberculosis and manage promptly.
SIDE EFFECTS:
• Cholesterol level increased• Dyspnea
• Nasopharyngitis
• Headache
• Constipation
• Decreased RBC
• Reduce in platelet counts
• Nausea & Vomiting
• Sleeplessness
• Liver enzymes increased
• Diarrhea
• bleeding
• Swelling
• Neutropenia
• Dizziness
PREGNANCY
The drug has no studies with the Jakavi 10mg use in pregnant women to inform drug-along with risks. Hence avoid becoming pregnancy during Jakavi 10mg tablet treatmentLACTATION
Avoid breastfeeding to infants during treatment with Jakavi 10mg. Excretion into human milk is unknownSTORAGE
Jakavi 10mg stored at 20°C to 25°CProtect away from light and moisture
Dispense in its original container
CONTACT DETAILS:
EMAIL: millionhealthpharmaceuticals@gmail.com
PHONE NO: +91-9940472902
Comments
Post a Comment